Article
Neurosciences
Mi Yang, Chunzhi Wang, Guocheng Zhao, Di Kong, Liju Liu, Shuai Yuan, Wei Chen, Can Feng, Zezhi Li
Summary: Objective: To investigate the effects of antipsychotic medication on oxidative stress markers in patients with schizophrenia. Methods: A systematic review and meta-analysis were conducted following the PRISMA guidelines. Results: Antipsychotic treatment resulted in changes in oxidative stress markers in schizophrenia patients, with different effects observed in different blood samples. However, the quality of the published literature was poor, limiting the accuracy of the findings.
CURRENT NEUROPHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Olga Plaza, Piotr Galecki, Agata Orzechowska, Malgorzata Galecka, Justyna Sobolewska-Nowak, Agata Szulc
Summary: Schizophrenia is a complex psychiatric disorder affected by both genetic and environmental factors. Pharmacogenetic research can help identify genetic variations that impact the response to antipsychotic medications, leading to more personalized and effective treatments. Genes involved in pharmacokinetics, as well as dopamine, serotonin, and glutamate neurotransmission, have been found to have a significant impact on antipsychotic response.
Article
Nursing
Bayan Abdulhaq, Latefa A. Dardas, Omar Sami
Summary: The study aimed to explore the knowledge, attitudes, practices, and adherence of psychiatrists in Jordan regarding metabolic monitoring guidelines for patients taking SGAs, as well as their perceived barriers. Findings showed that while most psychiatrists were aware of the guidelines, there were challenges in their implementation, with financial burden and lack of compliance from families and patients being major barriers identified.
PERSPECTIVES IN PSYCHIATRIC CARE
(2021)
Article
Psychiatry
Mushde Shakir, Anne E. Willems, Peter N. van Harten, Remko van Lutterveld, Diederik E. Tenback
Summary: Switching from a combination of first- and second-generation antipsychotics to monotherapy does not increase the relapse rate and may even reduce it in long-term inpatients.
SCHIZOPHRENIA RESEARCH
(2022)
Article
Psychiatry
Hiroyoshi Takeuchi, Marcos Sanches, Carol Borlido, Ofer Agid, Gary Remington
Summary: The study found that antipsychotic adherence, as measured by electronic adherence monitoring, was not significantly associated with illness/symptom severity at baseline and endpoint in patients with chronic schizophrenia. This suggests that individuals may be able to achieve clinical stability even with variations in adherence.
SCHIZOPHRENIA RESEARCH
(2021)
Article
Endocrinology & Metabolism
Diana Grajales, Patricia Vazquez, Monica Ruiz-Rosario, Eva Tuduri, Mercedes Mirasierra, Vitor Ferreira, Ana B. Hitos, Dora Koller, Pablo Zubiaur, Juan C. Cigudosa, Francisco Abad-Santos, Mario Vallejo, Ivan Quesada, Boaz Tirosh, Gil Leibowitz, Angela M. Valverde
Summary: Both olanzapine and aripiprazole induced adverse effects on beta cell function in female mice, leading to weight gain, glucose intolerance, and impaired insulin secretion. Aripiprazole had a stronger impact on metabolic alterations, likely due to its modulation of the serotonergic system.
Review
Health Care Sciences & Services
Alexandre Gonzalez-Rodriguez, Armand Guardia, Jose Antonio Monreal
Summary: Premenopausal women show better response to antipsychotic drugs, caution is needed in using hormone replacement therapy for postmenopausal women with schizophrenia, and raloxifene combined with antipsychotics can effectively improve psychotic and cognitive symptoms in postmenopausal women with schizophrenia and related disorders.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Behavioral Sciences
Mary Seeman
Summary: The review examines the potential role of intestinal organisms in response/non-response to antipsychotics, highlighting that current research in this area is mostly theoretical but showing increasing evidence from animal experiments and clinical trials on the impact of gut bacteria on drug response.
BEHAVIOURAL BRAIN RESEARCH
(2021)
Review
Psychiatry
Ophelie Rault, Bruno Romeo, Florence Butlen-Ducuing, Eirini Rari, Amine Benyamina, Catherine Martelli
Summary: Compared with the general population, there are more cannabis users among patients suffering from schizophrenia, and cannabis use seems to be associated with a higher risk of relapse. However, previous cannabis use or occasional use does not impact the efficacy of antipsychotic medication in patients with schizophrenia.
JOURNAL OF PSYCHIATRIC RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Nozomi Nakajima, Nao Mizoe, Fuminari Misawa, Toru Yamashita, Ryuhei So, Kohei Kitagawa, Kenichi Tanimoto, Yoshiki Kishi, Yasuo Fujii, Hiroyoshi Takeuchi
Summary: In patients with schizophrenia receiving long-term maintenance treatment with LAI-SGAs, the total daily antipsychotic dose generally remained stable, although an increase was observed in some patients. Age and initial antipsychotic dose were negatively associated with changes in total daily dose after 12 months of treatment initiation.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
(2021)
Article
Psychiatry
Emily Groenendaal, Sean Lynch, Rhea Dornbush, Lidia Klepacz, Stephen Ferrando
Summary: This study aimed to determine predictors of antipsychotic choice, including formulation (LAI vs oral) and class (FGA vs SGA), and clinical outcomes. The results showed that illness severity and duration of illness appear to drive the choice of LAI and FGA antipsychotic medication. This study supports the use of LAIs in patients with greater illness severity and discusses the rationales for prescribing LAIs to younger patients and FGAs to older patients.
JOURNAL OF PSYCHIATRIC RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Izabela Fulone, Marcus Tolentino Silva, Luciane Cruz Lopes
Summary: The study found that in Brazil, factors such as being female, age over 70, residing in the northeast region, and using certain types of antipsychotic medications were associated with an increased risk of switching between second-generation antipsychotics (SGAs). Risperidone was identified as the antipsychotic associated with the highest risk of switching, while clozapine had the lowest risk compared to other SGAs.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Medical Laboratory Technology
Georgios Schoretsanitis, Pierre Baumann, Andreas Conca, Otto Dietmaier, Giancarlo Giupponi, Gerhard Grunder, Martina Hahn, Xenia Hart, Ursula Havemann-Reinecke, Gudrun Hefner, Maxim Kuzin, Rainald Moessner, Daria Piacentino, Werner Steimer, Gerald Zernig, Christoph Hiemke
Summary: Therapeutic drug monitoring in the treatment of long-acting injectable antipsychotics plays a key role, with individual differences, genetic specificity, and clinical variables potentially affecting drug concentrations. For switching from oral formulations to LAI formulations, therapeutic drug monitoring is a more accurate method for dose selection.
THERAPEUTIC DRUG MONITORING
(2021)
Review
Clinical Neurology
Michael J. Doane, Kristine Ogden, Leona Bessonova, Amy K. O'Sullivan, Mauricio Tohen
Summary: This review highlighted the common suboptimal utilization patterns of SGAs, such as nonadherence, nonpersistence, and combination treatment, for patients with bipolar disorder in the US. These patterns were associated with increased healthcare resource use and costs. Strategies to improve SGA treatment continuity, particularly adherence, may enhance clinical and economic outcomes for individuals living with bipolar disorder.
NEUROPSYCHIATRIC DISEASE AND TREATMENT
(2021)
Review
Psychiatry
Giulia Paris, Irene Bighelli, Giacomo Deste, Spyridon Siafis, Johannes Schneider-Thoma, Yikang Zhu, John M. Davis, Antonio Vita, Stefan Leucht
Summary: This network meta-analysis evaluated the efficacy of short-acting IM second-generation antipsychotic drugs in patients with schizophrenia and schizophrenia-like disorders presenting acute agitation. The results showed that ziprasidone, olanzapine, aripiprazole, and haloperidol were more effective than placebo in calming patients at 2 hours. Olanzapine was somewhat more efficacious than aripiprazole.
SCHIZOPHRENIA RESEARCH
(2021)
Article
Psychiatry
Gin S. Malhi, Erica Bell, Darryl Bassett, Philip Boyce, Richard Bryant, Philip Hazell, Malcolm Hopwood, Bill Lyndon, Roger Mulder, Richard Porter, Ajeet B. Singh, Greg Murray
Summary: The 2020 clinical practice guidelines for mood disorders from the Royal Australian and New Zealand College of Psychiatrists offer updated guidance on managing mood disorders based on evidence and clinical experience. It is intended for use by psychiatrists, psychologists, primary care physicians, and others interested in mental health care. The guidelines build on previous versions and provide recommendations within an evidence-based framework supplemented by expert clinical consensus.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
(2021)
Editorial Material
Psychiatry
Gin S. Malhi, Erica Bell, Darryl Bassett, Philip Boyce, Malcolm Hopwood, Greg Murray, Richard Porter, Ajeet Singh, Roger Mulder
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
(2022)
Editorial Material
Psychiatry
Gin S. Malhi, Erica Bell, Darryl Bassett, Philip Boyce, Malcolm Hopwood, Greg Murray, Roger Mulder, Ajeet Singh, Richard Porter
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
(2022)
Editorial Material
Psychiatry
Gin S. Malhi, Erica Bell, Phil Boyce, Malcolm Hopwood, Darryl Bassett, Roger Mulder, Richard J. Porter
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
(2022)
Editorial Material
Psychiatry
Gin S. Malhi, Erica Bell, Zola Mannie, Phil Boyce, Malcolm Hopwood, Darryl Bassett, Roger Mulder, Richard J. Porter, Bill Lyndon
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
(2022)
Article
Public, Environmental & Occupational Health
Yun Zhao, Jian Zhao, Fenglian Xu, Philip Boyce, Caroline S. E. Homer
ASIA-PACIFIC JOURNAL OF PUBLIC HEALTH
(2022)
Letter
Psychiatry
Greg Murray, Erica Bell, Darryl Bassett, Philip Boyce, Richard Bryant, Philip Hazell, Malcolm Hopwood, Bill Lyndon, Roger Mulder, Richard Porter, Ajeet B. Singh, Gin S. Malhi
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
(2022)
Article
Clinical Neurology
Sabina Rai, Kristi R. Griffiths, Isabella A. Breukelaar, Ana R. Barreiros, Philip Boyce, Philip Hazell, Sheryl L. Foster, Gin S. Malhi, Anthony W. F. Harris, Mayuresh S. Korgaonkar
Summary: This study aimed to investigate common and shared neural mechanisms underlying mood disorders, as well as possible neural changes relating to illness chronicity. The study found that all three clinical groups had significantly lower connectivity compared to controls, and bipolar disorder group exhibited significant differences in certain connectivity features compared to the treatment-resistant depression group.
Editorial Material
Clinical Neurology
Gin S. Malhi, Erica Bell, Darryl Bassett, Philip Boyce, Richard Bryant, Philip Hazell, Malcolm Hopwood, Bill Lyndon, Roger Mulder, Richard Porter, Ajeet B. Singh, Greg Murray
Editorial Material
Clinical Neurology
Gin S. Malhi, Erica Bell, Philip Boyce, Roger Mulder, Darryl Bassett, Amber Hamilton, Grace Morris, Richard Bryant, Philip Hazell, Malcolm Hopwood, Bill Lyndon, Richard Porter, Ajeet B. Singh, Greg Murray
Editorial Material
Psychiatry
Gin S. Malhi, Erica Bell, Darryl Bassett, Philip Boyce, Richard Bryant, Malcolm Hopwood, Bill Lyndon, Roger Mulder, Richard Porter, Ajeet B. Singh, Greg Murray
Summary: This editorial compares the recommendations of two recently published national clinical practice guidelines for depression and highlights the agreement in advice on therapy selection and sequencing. Lifestyle and psychological interventions are emphasized, and there is broad consensus on medication choice and optimization strategies, making these guidelines a valuable resource.
BRITISH JOURNAL OF PSYCHIATRY
(2023)
Review
Clinical Neurology
Gin S. Malhi, Erica Bell, Darryl Bassett, Philip Boyce, Malcolm Hopwood, Roger Mulder, Richard Porter
Summary: This study extends current guidance on managing major depression by examining real-world cases and integrating evidence and experience into recommendations. The four fictional cases highlight the complexities clinicians face in managing mood disorders and stimulate discussion in diagnosis and treatment.
Editorial Material
Clinical Neurology
Gin S. Malhi, Erica Bell, Philip Boyce, Roger Mulder, Richard Porter
Article
Psychology, Multidisciplinary
David D. J. Cooper, Iain E. E. Perkes, John Lam-Po-Tang, Lara J. J. Farrell, Vlasios Brakoulias, Jessica R. R. Grisham
Summary: This study describes the development and evaluation of an online directory of clinicians offering evidence-based treatment for OCD, providing accessible information for people in Australia. The directory was found to meet usability standards and contributes to improving the treatment-seeking process for OCD patients in Australia.
AUSTRALIAN PSYCHOLOGIST
(2023)
Review
Psychiatry
Sarira El-Den, Lily Pham, Isobel Anderson, Shan Yang, Rebekah J. Moles, Claire L. O'Reilly, Philip Boyce, Karen Hazell Raine, Camille Raynes-Greenow
Summary: This systematic review compares perinatal depression (PND) screening recommendations from member countries of the Organisation for Economic Co-operation and Development (OECD). The study finds variations in screening timing, responsible provider, tools/assessments, follow-up mechanisms, and referral pathways among countries. Most recommendations support the use of the Edinburgh Postnatal Depression Scale, but there are differences in terminology and screening frequency. Clear and standardized recommendations based on current evidence are needed for early detection of PND.
ARCHIVES OF WOMENS MENTAL HEALTH
(2022)